Steady Progress against HER2-Positive Breast Cancer

被引：7
|
作者：
Hayes, Daniel F. [1 ]
机构：
[1] Univ Michigan, Breast Oncol Program, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2011年 / 365卷 / 14期
关键词：
ADJUVANT TRASTUZUMAB; DOXORUBICIN; PACLITAXEL; HER2;
D O I：
10.1056/NEJMe1101326
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1336 / 1338
页数：3
相关论文
共 50 条
  • [1] Immunotherapies against HER2-Positive Breast Cancer
    Duro-Sanchez, Santiago
    Alonso, Macarena Roman
    Arribas, Joaquin
    CANCERS, 2023, 15 (04)
  • [2] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [3] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
  • [4] Treatment of HER2-positive breast cancer
    Figueroa-Magalhaes, Maria Cristina
    Jelovac, Danijela
    Connolly, Roisin M.
    Wolff, Antonio C.
    BREAST, 2014, 23 (02): : 128 - 136
  • [5] Inflammatory HER2-positive breast cancer
    Dirix, Luc Y.
    Vermeulen, Peter B.
    LANCET ONCOLOGY, 2012, 13 (04): : 324 - 326
  • [6] Margetuximab for HER2-Positive Breast Cancer
    Cuellar, Sandra
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 573 - 575
  • [7] HER2-positive advanced breast cancer
    Robert, Nicholas J.
    Favret, Anne M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (02) : 293 - +
  • [8] Lapatinib in HER2-positive breast cancer
    Nelson, Roxanne
    LANCET ONCOLOGY, 2018, 19 (01): : 22 - 22
  • [9] Hereditary component of HER2-positive breast cancer
    Iglesias Campos, M.
    Jimena Marquez, A.
    Peralta Linero, R. J.
    Alba Conejo, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1325 - S1325
  • [10] Progression and treatment of HER2-positive breast cancer
    April Davoli
    Barbara A. Hocevar
    Thomas L. Brown
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 611 - 623
12345